APRE 10 Year Annualized Return and Average Annual Return

Growth of $10,000.00
Without Dividends Reinvested Into APRE


Also see:
APRE stock yearly return 2019
APRE stock yearly return 2020
APRE stock yearly return 2021
APRE stock yearly return 2022
APRE stock yearly return 2023
APRE stock yearly return 2024
APRE stock yearly return 2025
APRE YTD return
Compare APRE average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Start date: 10/04/2019
End date: 06/10/2026
Start price/share: $381.40
End price/share: $0.76
Dividends collected/share: $0.00
Total return: -99.80%
APRE Average Annual Return: -60.58%
Starting investment: $10,000.00
Ending investment: $19.78
Years: 6.69


APRE average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. Co.'s advanced synthetic lethality product candidate is ATRN-119, a clinical-stage small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR) a kinase that plays a critical role in DNA damage response (DDR). ATR and Checkpoint Kinase 1 are critical DDR kinases that prevent the collapse of replication forks into DNA double-strand breaks. It has completed all IND enabling studies for its oral, small molecule WEE1 inhibitor, APR-1051, and received U.S. Food and Drug Administration (FDA) clearance of its IND. The APRE average annual return since 2019 is shown above.

The Average Annual Return on the APRE average annual return since 2019 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether APRE average annual return since 2019 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the APRE average annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree APRE Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!
Aprea Therapeutics (APRE) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

APVO Average Annual Return
APYX Average Annual Return
AQST Average Annual Return
ARAY Average Annual Return
ARCT Average Annual Return
ARDT Average Annual Return
ARDX Average Annual Return
ARQT Average Annual Return
ARTL Average Annual Return
ARTV Average Annual Return
More Healthcare companies »
 

APRE 10 Year Annualized Return & Average Annual Return | www.AverageAnnualReturn.com | Copyright © 2021 - 2026, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.